From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following BrexitMark P. Lythgoe, Richard Sullivan, John Marriott et al.|The Lancet Oncology|2023Cited by 20
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapiesMark P. Lythgoe, Sarah P. Blagden, Richard Sullivan|The Lancet Oncology|2023Cited by 5
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspectiveSarah P. Blagden, Louise Brown, Ly‐Mee Yu et al.|British Journal of Cancer|2022Cited by 2
1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancerMariangela Saggese, Jonathan Krell, Matilda Duffy et al.|Annals of Oncology|2025Cited by 1